Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
United States
Tel: 800-GILEAD-5 or 650-574-3000
Fax: 650-522-5800
Website: http://www.gilead.com/
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
YEAR FOUNDED:
1987
LEADERSHIP:
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
CLINICAL TRIAL:
Please click here for clinical trial information.
1449 articles with Gilead Sciences, Inc.
-
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
-
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
-
Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019
4/18/2019
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes.
-
Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.
-
Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
4/12/2019
Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis.
-
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
-
The companies will collaborate on a clinical trial to combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of NASH.
-
Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019
4/11/2019
Data Demonstrate Role of Gilead HCV Medicines in Difficult–to-Treat Patient Populations and in Real-World Settings
-
Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019
4/11/2019
New Proof-of-Concept Data for Combination of Investigational FXR Agonist Cilofexor and ACC Inhibitor Firsocostat in NASH
-
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
-
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of its sales team, according to reports.
-
Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases
4/9/2019
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of five new global grants programs to continue to support investigator-sponsored research in chronic hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV and HIV co-infection, nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC)
-
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
4/5/2019
Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada® Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection
-
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
-
Gilead Sciences and Belgium-based Galapagos NV reported positive late-stage results from its FINCH 1 and FINCH 3 rheumatoid arthritis studies.
-
Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
3/28/2019
Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone
-
Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA)
3/28/2019
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today also announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis (RA).
-
Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study
3/28/2019
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis
-
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
3/26/2019
In Clinical Trials, Biktarvy Demonstrated High Efficacy, Few Interactions with Other Drugs and a High Barrier to Resistance Through 48 Weeks
-
Agenus Milestone Triggers $7.5M Payment from Gilead
3/13/2019
Agenus Inc announced that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc.